These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
18. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Bell SC; Barry PJ; De Boeck K; Drevinek P; Elborn JS; Plant BJ; Minić P; Van Braeckel E; Verhulst S; Muller K; Kanters D; Bellaire S; de Kock H; Geller DE; Conrath K; Van de Steen O; van der Ent K J Cyst Fibros; 2019 Sep; 18(5):700-707. PubMed ID: 31056441 [TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871 [TBL] [Abstract][Full Text] [Related]
20. A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. McKone EF; DiMango EA; Sutharsan S; Barto TL; Campbell D; Ahluwalia N; Higgins M; Owen CA; Tullis E J Cyst Fibros; 2021 Mar; 20(2):234-242. PubMed ID: 33339768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]